A Phase 2 Study of Linsitinib (OSI-906) in Pediatric and Adult Wild Type Gastrointestinal Stromal Tumors

TYPE OF SARCOMA: Gastrointestinal stromal tumors
DRUG: OSI-906
ACCRUAL STATUS: Completed

OVERALL STUDY PRINCIPAL INVESTIGATOR:
Margaret von Mehren, MD
Fox Chase Cancer Center

CLINICALTRIALS.GOV IDENTIFIER: NCT01560260

FOR STUDY DETAILS AND ELIGIBILITY CRITERIA: CLINICALTRIALS.GOV

IMPACT STATEMENT:
SARC022 tested a targeted therapy linsitinib in patients with wild type, primarily SDH-deficient Gastrointestinal tumors. This study demonstrated for the first time that it is feasible to do a clinical trial in this rare subset of patients. Linsitinib was found to be safe and well tolerated; while patients had disease control, there was no significant tumor shrinkage seen.

To learn more about this study or to contact the study research staff:

Back to top